172 related articles for article (PubMed ID: 30138161)
1. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis.
Khan MY; Dirweesh A; Khurshid T; Siddiqui WJ
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1309-1317. PubMed ID: 30138161
[TBL] [Abstract][Full Text] [Related]
2. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
[TBL] [Abstract][Full Text] [Related]
3. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Associates With Functional Alterations in Circulating microRNAs.
Monaghan TM; Seekatz AM; Markham NO; Yau TO; Hatziapostolou M; Jilani T; Christodoulou N; Roach B; Birli E; Pomenya O; Louie T; Lacy DB; Kim P; Lee C; Kao D; Polytarchou C
Gastroenterology; 2021 Jul; 161(1):255-270.e4. PubMed ID: 33844988
[TBL] [Abstract][Full Text] [Related]
4. Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives.
Dai C; Huang YH; Jiang M
World J Gastroenterol; 2024 Apr; 30(16):2179-2183. PubMed ID: 38690018
[TBL] [Abstract][Full Text] [Related]
5. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.
Ianiro G; Punčochář M; Karcher N; Porcari S; Armanini F; Asnicar F; Beghini F; Blanco-Míguez A; Cumbo F; Manghi P; Pinto F; Masucci L; Quaranta G; De Giorgi S; Sciumè GD; Bibbò S; Del Chierico F; Putignani L; Sanguinetti M; Gasbarrini A; Valles-Colomer M; Cammarota G; Segata N
Nat Med; 2022 Sep; 28(9):1913-1923. PubMed ID: 36109637
[TBL] [Abstract][Full Text] [Related]
6. [Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective].
Stallmach A; von Müller L; Storr M; Link A; Konturek PC; Solbach PC; Weiss KH; Wahler S; Vehreschild MJGT
Z Gastroenterol; 2024 Apr; 62(4):490-499. PubMed ID: 37187187
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transplant on Escherichia-Shigella gut composition and its potential role in the treatment of generalized anxiety disorder: A systematic review.
Baske MM; Timmerman KC; Garmo LG; Freitas MN; McCollum KA; Ren TY
J Affect Disord; 2024 Jun; 354():309-317. PubMed ID: 38499070
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.
Woodworth MH; Kraft CS; Meredith EJ; Mehta AK; Wang T; Mamo YT; Dhere T; Sitchenko KL; Patzer RE; Friedman-Moraco RJ
Transpl Infect Dis; 2018 Apr; 20(2):e12857. PubMed ID: 29446866
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Fecal Microbiota Transplantation on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis.
Pakmehr A; Mousavi SM; Ejtahed HS; Hoseini-Tavassol Z; Siadat SD; Hasani-Ranjbar S; Larijani B
Clin Ther; 2024 Feb; 46(2):e87-e100. PubMed ID: 38087724
[TBL] [Abstract][Full Text] [Related]
10. Fecal microbiota transplantation as a potential way to eradicate multiresistant microorganisms.
Dias C; Pipa S; Duarte-Ribeiro F; Mota M
IDCases; 2018; 13():e00432. PubMed ID: 30140609
[TBL] [Abstract][Full Text] [Related]
11. Current clostridium difficile treatments: Lessons that need to be learned from the clinical trials.
Tampaki EC; Tampakis A; Posabella A; Patsouris E; Kontzoglou K; Kouraklis G
Hum Vaccin Immunother; 2018; 14(12):2874-2875. PubMed ID: 30148975
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of different faecal microbiota transplantation protocols for
Ianiro G; Maida M; Burisch J; Simonelli C; Hold G; Ventimiglia M; Gasbarrini A; Cammarota G
United European Gastroenterol J; 2018 Oct; 6(8):1232-1244. PubMed ID: 30288286
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for
Shogbesan O; Poudel DR; Victor S; Jehangir A; Fadahunsi O; Shogbesan G; Donato A
Can J Gastroenterol Hepatol; 2018; 2018():1394379. PubMed ID: 30246002
[TBL] [Abstract][Full Text] [Related]
14. The use of faecal microbiota transplant as treatment for recurrent or refractory
Mullish BH; Quraishi MN; Segal JP; McCune VL; Baxter M; Marsden GL; Moore DJ; Colville A; Bhala N; Iqbal TH; Settle C; Kontkowski G; Hart AL; Hawkey PM; Goldenberg SD; Williams HRT
Gut; 2018 Nov; 67(11):1920-1941. PubMed ID: 30154172
[TBL] [Abstract][Full Text] [Related]
15. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
Hui W; Li T; Liu W; Zhou C; Gao F
PLoS One; 2019; 14(1):e0210016. PubMed ID: 30673716
[TBL] [Abstract][Full Text] [Related]
16. The Human Gut Microbiome - A Potential Controller of Wellness and Disease.
Kho ZY; Lal SK
Front Microbiol; 2018; 9():1835. PubMed ID: 30154767
[TBL] [Abstract][Full Text] [Related]
17. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
[TBL] [Abstract][Full Text] [Related]
18. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
Tariq R; Pardi DS; Bartlett MG; Khanna S
Clin Infect Dis; 2019 Apr; 68(8):1351-1358. PubMed ID: 30957161
[TBL] [Abstract][Full Text] [Related]
19. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.
Monaghan T; Mullish BH; Patterson J; Wong GK; Marchesi JR; Xu H; Jilani T; Kao D
Gut Microbes; 2019; 10(2):142-148. PubMed ID: 30183484
[TBL] [Abstract][Full Text] [Related]
20. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF
Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
